OKYO Pharma Limited (NASDAQ:OKYO – Get Free Report) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 48,300 shares, an increase of 21.7% from the June 30th total of 39,700 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 22,000 shares, the short-interest ratio is currently 2.2 days.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of OKYO Pharma in a research report on Thursday, July 11th.
View Our Latest Stock Report on OKYO
OKYO Pharma Price Performance
About OKYO Pharma
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Further Reading
- Five stocks we like better than OKYO Pharma
- Market Cap Calculator: How to Calculate Market Cap
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What Are Dividend Challengers?
- Why Call Options Volume for These 2 Stocks Spiked Together
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.